论文部分内容阅读
尿路上皮的原位癌侵入肌层的危险性很高,自从应用BCG膀胱内灌注治疗原位癌后,这一危险显著地降低。BCG灌注膀胱的治疗效效果不相同,这与采用不同的治疗方案及不同菌株的BCG有关,目前使用的BCG有Armand—Frappier、Tice、Pastcur等菌株,这些菌株都有治疗原位癌的作用。作者在这里报道了应用Evans菌株BCG治疗膀胱原位癌的结果。作者在1985年10月至1988午3月对18名患者用Evans菌株BCG进行了膀胱灌注治疗。其中17人是膀胱原位癌,平均随访时间是24个月。该组患者诊断标准是膀胱粘膜50％以上有病变或膀胱四个象限区域有三个发现有原位癌。治疗方案是每次
The risk of invasion of the urothelial carcinoma in situ from the urothelial carcinoma is very high, and this risk has decreased significantly since the application of BCG intravesical instillation in the treatment of carcinoma in situ. The therapeutic effect of BCG instillation of bladder is not the same, which is related to the use of different treatment options and different strains of BCG. Currently used BCG are Armand-Frappier, Tice, Pastcur and other strains, these strains have the effect of treatment of carcinoma in situ. Here the authors report the results of the application of Evans strain BCG in the treatment of bladder cancer in situ. Eighteen patients underwent bladder instillation with Evans strain BCG from October 1985 to March 1988. Of these, 17 were bladder cancer in situ and the average follow-up time was 24 months. The diagnostic criteria for this group of patients were more than 50% of bladder mucosal lesions or three of the four quadrant areas of the bladder with in situ carcinomas. Treatment plan is every time